Dr. Simron Singh - NETTER-2 trial: A paradigm shift in neuroendocrine tumor care | CRLS 2026

The Canadian Radiotheranostics Leaders’ Summit is an annual event held by the Canadian Nuclear Isotope Council (CNIC), the Canadian Medical Isotope Ecosystem (CMIE), and a consortium of academic centers (UHN, LHSC, BC Cancer, and CAMH) that aims to bring together leaders from across the global isotope supply chain, business and investment communities, government representatives, healthcare leaders, academics, students and more to shape Canada’s isotope leadership to support patients globally. About this session: Presentations – Canadian Contributions to Radiotheranostics: Trials, Investigators, and Impact Presentation 2 – NETTER-2 Trial: A paradigm shift in neuroendocrine tumor care Dr. Simron Singh, Sunnybrook Health Sciences Centre Session Chair: Dr. Luke Brzozowski, University Health Network Session overview: This session will spotlight Canada’s leadership in advancing radiotheranostics through examples of high-impact clinical trials and investigator-driven research. Featuring two presentations, speakers will explore recent landmark Canadian studies, including PR21 and NETTER-2, highlighting their design, outcomes, and implications for patient care. Attendees will gain insight into the role of Canadian investigators in shaping global evidence and driving innovation in targeted radiopharmaceutical therapies. The session will also examine how these contributions are influencing clinical practice, policy, and future research directions. Together, the presentations will underscore Canada’s growing impact on the evolving landscape of precision oncology.